Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low-risk Myelodysplastic Syndrome”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00939159
What this trial is testing

Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome
M.D. Anderson Cancer Center 17
Testing effectiveness (Phase 2)Looking for participantsNCT06046313
What this trial is testing

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
First Affiliated Hospital of Zhejiang University 120
Testing effectiveness (Phase 2)UnknownNCT03412266
What this trial is testing

RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT

Who this might be right for
Myelodysplastic Syndromes
Peking University People's Hospital 50
Testing effectiveness (Phase 2)Study completedNCT00600938
What this trial is testing

Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload

Who this might be right for
Transfusional Iron OverloadTransfusional Hemosiderosis
Novartis Pharmaceuticals 197
Large-scale testing (Phase 3)Study completedNCT01196715
What this trial is testing

Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndrome
Barts & The London NHS Trust 360
Testing effectiveness (Phase 2)UnknownNCT00437450
What this trial is testing

Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid

Who this might be right for
Anemia in Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 99
Not applicableStudy completedNCT02757989
What this trial is testing

Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

Who this might be right for
MDS
Groupe Francophone des Myelodysplasies 79
Testing effectiveness (Phase 2)Study completedNCT01736683
What this trial is testing

Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

Who this might be right for
AnemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+3 more
Merck Sharp & Dohme LLC 74
Large-scale testing (Phase 3)Study completedNCT02175277
What this trial is testing

Darbepoetin Alfa MDS Companion Protocol

Who this might be right for
Myelodysplastic Syndrome (MDS)
Amgen 9
Early research (Phase 1)Ended earlyNCT02452983
What this trial is testing

Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndromes
Gustavo Rivero 14
Early research (Phase 1)Ended earlyNCT01362036
What this trial is testing

Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia

Who this might be right for
Myelodysplastic Syndrome (MDS)
Tarix Pharmaceuticals 2
Testing effectiveness (Phase 2)WithdrawnNCT00446602
What this trial is testing

Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic SyndromesAnemia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Large-scale testing (Phase 3)Study completedNCT02631070
What this trial is testing

Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Celgene 229
Testing effectiveness (Phase 2)Study completedNCT00411905
What this trial is testing

Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 45
Early research (Phase 1)Not Yet RecruitingNCT07753148
What this trial is testing

Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation

Who this might be right for
Clonal Cytopenia of Undetermined Significance (CCUS)Low-Risk Myelodysplastic Syndrome (LR-MDS)
Regeneron Pharmaceuticals 52
Testing effectiveness (Phase 2)Ended earlyNCT01513317
What this trial is testing

A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Janssen Research & Development, LLC 76
Testing effectiveness (Phase 2)Looking for participantsNCT07319845
What this trial is testing

TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Takeda 42
Testing effectiveness (Phase 2)Study completedNCT00303472
What this trial is testing

Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)

Who this might be right for
ThrombocytopeniaMDSMyelodysplastic Syndromes+1 more
Amgen 72
Post-approval studies (Phase 4)Study completedNCT00488436
What this trial is testing

Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
PETHEMA Foundation 25
Testing effectiveness (Phase 2)Study completedNCT01772953
What this trial is testing

Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
Center for International Blood and Marrow Transplant Research 40
Next Page